JP2021515772A5 - - Google Patents

Info

Publication number
JP2021515772A5
JP2021515772A5 JP2020546481A JP2020546481A JP2021515772A5 JP 2021515772 A5 JP2021515772 A5 JP 2021515772A5 JP 2020546481 A JP2020546481 A JP 2020546481A JP 2020546481 A JP2020546481 A JP 2020546481A JP 2021515772 A5 JP2021515772 A5 JP 2021515772A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
patient
composition according
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020546481A
Other languages
English (en)
Japanese (ja)
Other versions
JP7426940B2 (ja
JP2021515772A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/021034 external-priority patent/WO2019173530A1/en
Publication of JP2021515772A publication Critical patent/JP2021515772A/ja
Publication of JP2021515772A5 publication Critical patent/JP2021515772A5/ja
Priority to JP2023207363A priority Critical patent/JP2024028919A/ja
Application granted granted Critical
Publication of JP7426940B2 publication Critical patent/JP7426940B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020546481A 2018-03-06 2019-03-06 心血管リスクを低減するためのpcsk9阻害剤の使用 Active JP7426940B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023207363A JP2024028919A (ja) 2018-03-06 2023-12-08 心血管リスクを低減するためのpcsk9阻害剤の使用

Applications Claiming Priority (35)

Application Number Priority Date Filing Date Title
US201862639407P 2018-03-06 2018-03-06
US62/639,407 2018-03-06
US201862640361P 2018-03-08 2018-03-08
US62/640,361 2018-03-08
US201862641082P 2018-03-09 2018-03-09
US62/641,082 2018-03-09
US201862641918P 2018-03-12 2018-03-12
US62/641,918 2018-03-12
US201862657495P 2018-04-13 2018-04-13
US62/657,495 2018-04-13
US201862683695P 2018-06-12 2018-06-12
US62/683,695 2018-06-12
US201862688622P 2018-06-22 2018-06-22
US62/688,622 2018-06-22
US201862717530P 2018-08-10 2018-08-10
US62/717,530 2018-08-10
US201862736284P 2018-09-25 2018-09-25
US62/736,284 2018-09-25
US201862744008P 2018-10-10 2018-10-10
US62/744,008 2018-10-10
US201862746319P 2018-10-16 2018-10-16
US62/746,319 2018-10-16
US201862770530P 2018-11-21 2018-11-21
US62/770,530 2018-11-21
US201862775219P 2018-12-04 2018-12-04
US62/775,219 2018-12-04
US201962797680P 2019-01-28 2019-01-28
US62/797,680 2019-01-28
US201962802545P 2019-02-07 2019-02-07
US62/802,545 2019-02-07
US201962806313P 2019-02-15 2019-02-15
US62/806,313 2019-02-15
EP19305247 2019-03-04
EP19305247.9 2019-03-04
PCT/US2019/021034 WO2019173530A1 (en) 2018-03-06 2019-03-06 Use of pcsk9 inhibitor for reducing cardiovascular risk

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023207363A Division JP2024028919A (ja) 2018-03-06 2023-12-08 心血管リスクを低減するためのpcsk9阻害剤の使用

Publications (3)

Publication Number Publication Date
JP2021515772A JP2021515772A (ja) 2021-06-24
JP2021515772A5 true JP2021515772A5 (enExample) 2022-03-10
JP7426940B2 JP7426940B2 (ja) 2024-02-02

Family

ID=66001316

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020546481A Active JP7426940B2 (ja) 2018-03-06 2019-03-06 心血管リスクを低減するためのpcsk9阻害剤の使用
JP2023207363A Pending JP2024028919A (ja) 2018-03-06 2023-12-08 心血管リスクを低減するためのpcsk9阻害剤の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023207363A Pending JP2024028919A (ja) 2018-03-06 2023-12-08 心血管リスクを低減するためのpcsk9阻害剤の使用

Country Status (11)

Country Link
US (1) US20190292273A1 (enExample)
EP (1) EP3762026B1 (enExample)
JP (2) JP7426940B2 (enExample)
KR (1) KR20200129127A (enExample)
CN (1) CN113015543A (enExample)
AU (1) AU2019231703A1 (enExample)
CA (1) CA3092936A1 (enExample)
IL (1) IL277127B2 (enExample)
MX (1) MX2020009246A (enExample)
TW (2) TW201945401A (enExample)
WO (1) WO2019173530A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402707B2 (en) 2008-07-22 2016-08-02 Neuravi Limited Clot capture systems and associated methods
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
EP2629684B1 (en) 2010-10-22 2018-07-25 Neuravi Limited Clot engagement and removal system
SG192117A1 (en) 2011-01-28 2013-08-30 Sanofi Sa Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
ES3029850T3 (en) 2011-03-09 2025-06-25 Neuravi Ltd A clot retrieval device for removing occlusive clot from a blood vessel
US12076037B2 (en) 2011-03-09 2024-09-03 Neuravi Limited Systems and methods to restore perfusion to a vessel
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
US9433429B2 (en) 2013-03-14 2016-09-06 Neuravi Limited Clot retrieval devices
TR201901830T4 (tr) 2013-03-14 2019-03-21 Neuravi Ltd Kan damarlarından akut tıkanıkların giderilmesine yönelik cihazlar ve metotlar.
EP3536252B1 (en) 2013-03-14 2023-09-13 Neuravi Limited A clot retrieval device for removing occlusive clot from a blood vessel
CN118105480A (zh) 2013-11-12 2024-05-31 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
US11253278B2 (en) 2014-11-26 2022-02-22 Neuravi Limited Clot retrieval system for removing occlusive clot from a blood vessel
US10617435B2 (en) 2014-11-26 2020-04-14 Neuravi Limited Clot retrieval device for removing clot from a blood vessel
HK1247066A1 (zh) 2014-11-26 2018-09-21 Neuravi Limited 从血管除去阻塞性血栓的取血栓装置
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗pcsk9阻害抗体
CN109906058B (zh) 2016-09-06 2022-06-07 尼尔拉维有限公司 用于从血管移除闭塞凝块的凝块取回装置
US10842498B2 (en) * 2018-09-13 2020-11-24 Neuravi Limited Systems and methods of restoring perfusion to a vessel
US11406416B2 (en) 2018-10-02 2022-08-09 Neuravi Limited Joint assembly for vasculature obstruction capture device
CA3155065A1 (en) * 2019-09-19 2021-03-25 Innovent Biologics (Suzhou) Co., Ltd. Use of anti-pcsk9 antibody in method for preventing or treating cholesterol-related disease
US11712231B2 (en) 2019-10-29 2023-08-01 Neuravi Limited Proximal locking assembly design for dual stent mechanical thrombectomy device
US11517340B2 (en) 2019-12-03 2022-12-06 Neuravi Limited Stentriever devices for removing an occlusive clot from a vessel and methods thereof
US11717308B2 (en) 2020-04-17 2023-08-08 Neuravi Limited Clot retrieval device for removing heterogeneous clots from a blood vessel
US11730501B2 (en) 2020-04-17 2023-08-22 Neuravi Limited Floating clot retrieval device for removing clots from a blood vessel
US11871946B2 (en) 2020-04-17 2024-01-16 Neuravi Limited Clot retrieval device for removing clot from a blood vessel
US11737771B2 (en) 2020-06-18 2023-08-29 Neuravi Limited Dual channel thrombectomy device
US11937836B2 (en) 2020-06-22 2024-03-26 Neuravi Limited Clot retrieval system with expandable clot engaging framework
US11395669B2 (en) 2020-06-23 2022-07-26 Neuravi Limited Clot retrieval device with flexible collapsible frame
US11439418B2 (en) 2020-06-23 2022-09-13 Neuravi Limited Clot retrieval device for removing clot from a blood vessel
US11864781B2 (en) 2020-09-23 2024-01-09 Neuravi Limited Rotating frame thrombectomy device
US11937837B2 (en) 2020-12-29 2024-03-26 Neuravi Limited Fibrin rich / soft clot mechanical thrombectomy device
US12029442B2 (en) 2021-01-14 2024-07-09 Neuravi Limited Systems and methods for a dual elongated member clot retrieval apparatus
US12064130B2 (en) 2021-03-18 2024-08-20 Neuravi Limited Vascular obstruction retrieval device having sliding cages pinch mechanism
US11974764B2 (en) 2021-06-04 2024-05-07 Neuravi Limited Self-orienting rotating stentriever pinching cells
CN115413625A (zh) * 2022-08-22 2022-12-02 郑咏秋 一种类风湿性冠心病动物模型及其构建方法和应用
CN118116596B (zh) * 2024-04-25 2024-07-02 青岛宝迈得生物科技有限公司 基于大数据分析的肝胆与心血管疾病共发风险评估方法
CN121015868B (zh) * 2025-10-29 2026-03-20 核工业四一六医院 Pcsk9抑制剂在制备用于治疗甲减伴高脂血症的药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
SG192117A1 (en) 2011-01-28 2013-08-30 Sanofi Sa Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
HUE069234T2 (hu) 2011-09-16 2025-02-28 Regeneron Pharma Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
EP4338805B1 (en) * 2012-06-29 2025-06-04 Amarin Pharmaceuticals Ireland Limited Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal myocardial infarction in a subject on statin therapy
ES2914978T3 (es) * 2013-10-11 2022-06-20 Sanofi Biotechnology Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
CA2955304C (en) * 2014-07-16 2023-12-12 Sanofi Biotechnology Methods for treating high cardiovascular risk patients with hypercholesterolemia
EA039310B1 (ru) * 2015-02-26 2022-01-12 Санофи Байотекнолоджи Способы снижения сердечно-сосудистого риска
JP2018523684A (ja) * 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗pcsk9阻害抗体

Similar Documents

Publication Publication Date Title
JP2021515772A5 (enExample)
IL277127B1 (en) Using pcsk9 tracking to reduce cardiovascular risk
JP2022133396A5 (enExample)
JP2022177142A5 (enExample)
JP2024147744A (ja) 心血管リスクを低減させる方法
JP2017528427A5 (enExample)
JP2017509624A5 (enExample)
JP2019514907A5 (enExample)
CN107922507B (zh) 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者
JP2017160208A5 (enExample)
JP2016538277A5 (enExample)
JP2022033868A5 (enExample)
JP2016538248A5 (enExample)
JP2017522316A5 (enExample)
JP2014516953A5 (enExample)
JP2024531151A5 (enExample)
FI3416684T3 (fi) Menetelmiä ateroskleroosin hoitamiseksi tai ehkäisemiseksi antamalla ANGPTL3:n inhibiittoria
JP2008528638A5 (enExample)
Lorenzatti et al. Role of anti-inflammatory interventions in coronary artery disease: understanding the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS)
CN106029096A (zh) 用于治疗具有未被中等剂量他汀疗法充分控制的高胆固醇血症的患者的方法
JP2019512472A5 (enExample)
JP2022532927A5 (enExample)
JP2019533715A5 (enExample)
RU2012114854A (ru) Способы лечения псориаза
JP2020522544A5 (enExample)